Our viral vaccine capabilitiess include generation, production, purification and analysis of DNA and RNA viruses manufactured on mammalian cell lines.
Our contribution to Global Health
In pursuit of increasing global vaccination coverage, we are committed to develop technologies that substantially lower the cost of vaccine manufacturing. Hereto, we develop highly intensified production process for viral vaccines, HIP-Vax, to reduce cost of product by decreasing CAPEX and cost of goods. Furthermore, we have developed SCOUT® technology to reduce development timelines and time to market. As it is known that costs of capital (53%) and cost of failure (40%) are the biggest cost attributes to a vaccine price paid by consumers, our platforms substantially aid global health initiatives to reach their goals.
Viral vaccines track record
We have extensive experience in manufacturing a wide range of viruses including polio, measles, rubella, influenza and rotavirus. We are proud to have delivered vaccine products for phase-I and phase-II clinical studies in both the EU and US markets. Our experience in the field, anchored in production, purification, and testing protocols, has resulted in a successful track record in delivering vaccine products. For example, in a collaboration with PATH, we have manufactured GMP virus stocks of several novel oral polio vaccine strains. In addition, in collaboration with Prof. Marcellus Ubbink (Leiden University, Netherlands) we are developing a very promising new class of vaccines: self-adjuvating, thermostable influenza vaccines.
Viral vaccines technologies
HIP-Vax technology®
Under the HIP-Vax® brand, we market our process development services and know-how which enables fast and low-cost vaccine manufacturing using bioprocess intensification technologies.
SATIRN® technology
The SATIRN® technology delivers a platform to manufacture potent, self-adjuvating, thermostable, membrane protein-based vaccines.
SCOUT® technology
The SCOUT® technology provides for an effective tool for “Design-of-Experiments” (DoE) approaches. It uses a miniaturized production and purification platform to rapidly develop multivariate processes.
Process development
We develop scalable, robust and GMP-compliant manufacturing processes for viral vaccines.
Upstream process development
We deliver scalable and robust GMP-compliant processes for viral vaccines.
Downstream process development
We deliver scalable and robust GMP-compliant processes for viral vaccines.
Analytical development
We perform and develop all the required product-specific release and stability assays for your viral vaccine.
In silico cost modeling
We often perform in silico cost modeling of manufacturing processes for viral vaccines.
Related resources
Adenoviruses have been shown to be very effective vehicles for delivering genetic material to cells and are therefore in demand to develop gene therapies and vaccine products. The road from…
Adenovirus (Ad) vectors are used to develop gene therapy products and vaccines. Decades of research stand behind these vectors which have gone through several iterations and improvements to make them…
Adenoviruses have been explored for gene therapy purposes for many decades. They are DNA viruses, with a double-stranded DNA genome of around 26-45 kilobases. Adenoviruses have been isolated from a…
You’ve developed a candidate viral vaccine or viral vector product, and initial preclinical data are showing excellent efficacy. Now you’re ready to scale up for IND application and testing in…
Talk to our experts
